1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary
Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers,
Challenges, Trends
4. Voice of Customer
5. Clinical Trial Analysis
5.1. Ongoing Clinical Trials
5.2. Completed Clinical Trials
5.3. Terminated Clinical Trials
5.4. Breakdown of Pipeline, By Development
Phase
5.5. Breakdown of Pipeline, By Status
5.6. Breakdown of Pipeline, By Study Type
5.7. Breakdown of Pipeline, By Region
5.8. Clinical Trials Heat Map
6. Global Narcolepsy Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By
Type (Type 1, Type 2, Others)
6.2.2. By
Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
6.2.3. By
Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
6.2.4. By
End User (Hospitals, Clinics, Retail Pharmacies, Others)
6.2.5. By
Company (2024)
6.3. Product Map
7. North America Narcolepsy Market Outlook
7.1. Market Size &
Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By
Type (Type 1, Type 2, Others)
7.2.2. By
Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
7.2.3. By
Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
7.2.4. By
End User (Hospitals, Clinics, Retail Pharmacies, Others)
7.2.5. By
Country
7.3. North America: Country Analysis
7.3.1. United States Narcolepsy
Market Outlook
7.3.1.1. Market Size
& Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share
& Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Diagnosis
7.3.1.2.3. By Treatment
7.3.1.2.4. By End User
7.3.2. Canada Narcolepsy Market Outlook
7.3.2.1. Market Size
& Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share
& Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Diagnosis
7.3.2.2.3. By Treatment
7.3.2.2.4. By End User
7.3.3. Mexico Narcolepsy Market Outlook
7.3.3.1. Market Size
& Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share
& Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Diagnosis
7.3.3.2.3. By Treatment
7.3.3.2.4. By End User
8. Europe Narcolepsy Market Outlook
8.1. Market Size &
Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By
Treatment Type (Chest Pain, Headache, Fever, Pneumonia, Hypertension, Fatigue,
Sleep Problems)
8.2.2. By
Type (Type 1, Type 2, Others)
8.2.3. By
Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
8.2.4. By
Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
8.2.5. By
End User (Hospitals, Clinics, Retail Pharmacies, Others)
8.2.6. By
Country
8.3. Europe: Country Analysis
8.3.1. France Narcolepsy Market Outlook
8.3.1.1. Market Size
& Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share
& Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Diagnosis
8.3.1.2.3. By Treatment
8.3.1.2.4. By End User
8.3.2. Germany Narcolepsy Market Outlook
8.3.2.1. Market Size
& Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share
& Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Diagnosis
8.3.2.2.3. By Treatment
8.3.2.2.4. By End User
8.3.3. United Kingdom Narcolepsy
Market Outlook
8.3.3.1. Market Size
& Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share
& Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Diagnosis
8.3.3.2.3. By Treatment
8.3.3.2.4. By End User
8.3.4. Italy Narcolepsy Market Outlook
8.3.4.1. Market Size
& Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share
& Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Diagnosis
8.3.4.2.3. By Treatment
8.3.4.2.4. By End User
8.3.5. Spain Narcolepsy Market Outlook
8.3.5.1. Market Size
& Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share
& Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Diagnosis
8.3.5.2.3. By Treatment
8.3.5.2.4. By End User
9. Asia-Pacific Narcolepsy Market Outlook
9.1. Market Size &
Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By
Type (Type 1, Type 2, Others)
9.2.2. By
Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
9.2.3. By
Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
9.2.4. By
End User (Hospitals, Clinics, Retail Pharmacies, Others)
9.2.5. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. China Narcolepsy Market Outlook
9.3.1.1. Market Size
& Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share
& Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Diagnosis
9.3.1.2.3. By Treatment
9.3.1.2.4. By End User
9.3.2. India Narcolepsy Market Outlook
9.3.2.1. Market Size
& Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share
& Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Diagnosis
9.3.2.2.3. By Treatment
9.3.2.2.4. By End User
9.3.3. Japan Narcolepsy Market Outlook
9.3.3.1. Market Size
& Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share
& Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Diagnosis
9.3.3.2.3. By Treatment
9.3.3.2.4. By End User
9.3.4. South Korea Narcolepsy
Market Outlook
9.3.4.1. Market Size
& Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share
& Forecast
9.3.4.2.1. By Type
9.3.4.2.2. By Diagnosis
9.3.4.2.3. By Treatment
9.3.4.2.4. By End User
9.3.5. Australia Narcolepsy
Market Outlook
9.3.5.1. Market Size
& Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share
& Forecast
9.3.5.2.1. By Type
9.3.5.2.2. By Diagnosis
9.3.5.2.3. By Treatment
9.3.5.2.4. By End User
10. South
America Narcolepsy Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type (Type 1,
Type 2, Others)
10.2.2. By Diagnosis
(Polysomnogram, Multiple Sleep Latency Test, Others)
10.2.3. By Treatment
(Stimulants, Antidepressants, Sodium
Oxybate, Others)
10.2.4. By End User
(Hospitals, Clinics, Retail
Pharmacies, Others)
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Narcolepsy Market Outlook
10.3.1.1. Market Size
& Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share
& Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Diagnosis
10.3.1.2.3. By Treatment
10.3.1.2.4. By End User
10.3.2. Argentina Narcolepsy
Market Outlook
10.3.2.1. Market Size
& Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share
& Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Diagnosis
10.3.2.2.3. By Treatment
10.3.2.2.4. By End User
10.3.3. Colombia Narcolepsy
Market Outlook
10.3.3.1. Market Size
& Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share
& Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Diagnosis
10.3.3.2.3. By Treatment
10.3.3.2.4. By End User
11. Middle
East and Africa Narcolepsy Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Type (Type 1,
Type 2, Others)
11.2.2. By Diagnosis
(Polysomnogram, Multiple Sleep Latency Test, Others)
11.2.3. By Treatment
(Stimulants, Antidepressants, Sodium
Oxybate, Others)
11.2.4. By End User
(Hospitals, Clinics, Retail
Pharmacies, Others)
11.2.5. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Narcolepsy
Market Outlook
11.3.1.1. Market Size
& Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share
& Forecast
11.3.1.2.1. By Type
11.3.1.2.2. By Diagnosis
11.3.1.2.3. By Treatment
11.3.1.2.4. By End User
11.3.2. Saudi Arabia Narcolepsy
Market Outlook
11.3.2.1. Market Size
& Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share
& Forecast
11.3.2.2.1. By Type
11.3.2.2.2. By Diagnosis
11.3.2.2.3. By Treatment
11.3.2.2.4. By End User
11.3.3. UAE Narcolepsy Market Outlook
11.3.3.1. Market Size
& Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share
& Forecast
11.3.3.2.1. By Type
11.3.3.2.2. By Diagnosis
11.3.3.2.3. By Treatment
11.3.3.2.4. By End User
12. Market
Dynamics
12.1. Drivers
12.1.1 Increase in Prevalence of Narcolepsy
12.1.2 Growing Initiatives by Government Organizations
12.2. Challenges
12.2.1 Adverse effect related to narcolepsy drugs.
12.2.2 Misdiagnosis related to narcolepsy treatment
13. Market
Trends & Developments
13.1. Recent Development
13.2. Mergers & Acquisitions
13.3. Product Launches
14. Global Narcolepsy Market: SWOT Analysis
15. Porter’s Five Forces Analysis
15.1. Competition in the Industry
15.2. Potential of New Entrants
15.3. Power of Suppliers
15.4. Power of Customers
15.5. Threat of Substitute Products
16. Competitive
Landscape
16.1. Business Overview
16.2. Product Offerings
16.3. Recent Developments
16.4. Financials (As Reported)
16.5. Key Personnel
16.6. SWOT Analysis
18.6.1 Jazz Pharmaceuticals Plc.
18.6.2 BIOPROJET.
18.6.3 Arena Pharmaceuticals, Inc.
18.6.4 Graymark Healthcare, Inc.
18.6.5 Mylan N.V.
18.6.6 Teva Pharmaceutical Industries Ltd.
18.6.7 Novartis AG.
18.6.8 Shire.
18.6.9 Shionogi Inc.
18.6.10 Ligand Pharmaceuticals, Inc.
17. Strategic Recommendations
18. About Us & Disclaimer